2024
MP24-20 IMPACT OF MENTAL HEALTH ILLNESS ON ADHERENCE TO SURVEILLANCE AND TREATMENT GUIDELINES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Grajales V, Duan Z, Tan W, Contieri R, Myers A, Zhao H, Giordano S, Williams S, Kamat A. MP24-20 IMPACT OF MENTAL HEALTH ILLNESS ON ADHERENCE TO SURVEILLANCE AND TREATMENT GUIDELINES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS. Journal Of Urology 2024, 211: e401. DOI: 10.1097/01.ju.0001008860.46052.c4.20.Peer-Reviewed Original ResearchTargeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
Alcantara M, Tang W, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal S, Kortylewski M. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. Frontiers In Immunology 2024, 14: 1274781. PMID: 38259453, PMCID: PMC10800835, DOI: 10.3389/fimmu.2023.1274781.Peer-Reviewed Original ResearchImmune checkpoint blockadeDendritic cellsCancer patientsBladder cancerT cellsTumor-associated antigen-presenting cellsTherapeutic efficacyLesser extent IL-10T cell-based immunotherapyImmune checkpoint inhibitorsTumor immune evasionAntitumor immune responseCD8 T cellsRegulatory T cellsBladder cancer immunotherapyCell-based immunotherapyAntigen-presenting cellsSTAT3 activationRenal cancer patientsBladder cancer patientsImmune cell activityMyeloid immune cellsICB resistanceIpilimumab immunotherapyCheckpoint inhibitors
2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal Of Urology 2023, 210: 763-770. PMID: 37535836, DOI: 10.1097/ju.0000000000003639.Peer-Reviewed Original ResearchTransurethral resection of bladder tumorResection of bladder tumorNonmuscle-invasive bladder cancerTransurethral resectionBladder tumorsActive surveillanceBladder cancerScoring systemNonmuscle-invasive bladder cancer patientsAbsence of gross hematuriaMultivariate Cox proportional hazards analysisRisk factorsNonmuscle-invasive bladder tumorsNegative urinary cytologyCox proportional hazards analysisMedian Follow-UpMultivariate Cox regressionBladder cancer patientsProportional hazards analysisUrinary cytologyGross hematuriaT stageLandmark time pointsFollow-upCox regressionCell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. European Urology Oncology 2023, 6: 516-524. PMID: 37087309, PMCID: PMC10587361, DOI: 10.1016/j.euo.2023.03.008.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerNeoadjuvant chemotherapyCooperative group trialsCell-free DNA methylationProspective cooperative group trialsPathologic responseBladder cancerRadical cystectomyNAC responseChemotherapy responseTreatment responseGroup trialsCycles of chemotherapyNeoadjuvant chemotherapy responseAdvanced bladder cancerStandard of careBladder cancer patientsIndependent predictive abilityGene expression signaturesMetastatic diseaseCancer patientsPredictive biomarkersPathologic respondersCurrent exploratory analysisInvasive approachMP63-06 BACILLUS CALMETTE-GUERIN VS IMMEDIATE RADICAL CYSTECTOMY IN EAU DEFINED VERY HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. MP63-06 BACILLUS CALMETTE-GUERIN VS IMMEDIATE RADICAL CYSTECTOMY IN EAU DEFINED VERY HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS. Journal Of Urology 2023, 209: e873. DOI: 10.1097/ju.0000000000003321.06.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancer patientsInvasive bladder cancer patientsBladder cancer patientsCancer patientsMP63-11 ADVANCED AGE (>70 YEARS) DOES NOT AFFECT ONCOLOGICAL OUTCOMES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH ADEQUATE BACILLUS CALMETTE-GUERIN: A COMPETING RISK ANALYSIS FROM a TERTIARY CARE CENTER.
Contieri R, Grajales V, Tan W, Bree K, Hensley P, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. MP63-11 ADVANCED AGE (>70 YEARS) DOES NOT AFFECT ONCOLOGICAL OUTCOMES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH ADEQUATE BACILLUS CALMETTE-GUERIN: A COMPETING RISK ANALYSIS FROM a TERTIARY CARE CENTER. Journal Of Urology 2023, 209: e875. DOI: 10.1097/ju.0000000000003321.11.Peer-Reviewed Original ResearchA0722 Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients
Contieri R, Hensley P, Grajales V, Tan W, Bree K, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. A0722 Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients. European Urology 2023, 83: s1023-s1024. DOI: 10.1016/s0302-2838(23)00766-2.Peer-Reviewed Original ResearchBladder Cancer Radiation Oncology of the Future: Prognostic Modelling, Radiomics, and Treatment Planning With Artificial Intelligence
Moore N, McWilliam A, Aneja S. Bladder Cancer Radiation Oncology of the Future: Prognostic Modelling, Radiomics, and Treatment Planning With Artificial Intelligence. Seminars In Radiation Oncology 2023, 33: 70-75. PMID: 36517196, DOI: 10.1016/j.semradonc.2022.10.009.Peer-Reviewed Original ResearchConceptsArtificial intelligenceMachine learningReliability of algorithmAccurate predictive modelsEfficient creationIntelligenceBladder cancer patientsRadiation oncology patientsAlgorithmPrognostic modellingRoutine clinical useClinical outcomesOncology patientsClinical recordsCancer patientsBladder cancerPredictive modelTreatment planClinical useMultiple treatment plansClinical implementationNext stepRadiation oncologyTreatment planningInterpretability
2022
Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314. Journal Of Clinical Oncology 2022, 40: 4506-4506. DOI: 10.1200/jco.2022.40.16_suppl.4506.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBladder cancer patientsPathologic responseTreatment responseCell-free DNA methylationCancer patientsMuscle-invasive bladder cancer patientsMuscle-invasive bladder cancerCycles of chemotherapyStandard neoadjuvant chemotherapyCooperative group trialsStandard of careProspective cooperative group trialsIndependent predictive abilityRadical cystectomyPredictive biomarkersPathologic respondersBladder cancerGroup trialsMR scoreBlood samplesChemotherapyPatientsPlasma samplesResponse scores
2020
776 Intravesical chemohyperthermia (HIVEC-E) in BCG unresponsive non-muscle invasive bladder cancer patients: Oncological outcomes of a multi-centre European registry
Tan W, Chiancone F, Fedelini P, Boormans J, De Jong J, Wilby D, Robinson R, Poggio M, Escudero J, Goizueta F, Plata A, Vögeli T, Escandón A, Nzeh C, De La Morena J, Moreno J, Guerrero F, Torres J, Hendricksen K. 776 Intravesical chemohyperthermia (HIVEC-E) in BCG unresponsive non-muscle invasive bladder cancer patients: Oncological outcomes of a multi-centre European registry. European Urology Open Science 2020, 19: e1181-e1182. DOI: 10.1016/s2666-1683(20)33376-0.Peer-Reviewed Original ResearchInequity in selective referral to high-volume hospitals for genitourinary malignancies
Berg S, Tully K, Sahraoui A, Tan W, Krimphove M, Marchese M, Lipsitz S, Noldus J, Trinh Q. Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology Seminars And Original Investigations 2020, 38: 582-589. PMID: 32217041, DOI: 10.1016/j.urolonc.2020.02.013.Peer-Reviewed Original ResearchConceptsHigh-volume hospitalsBladder cancerPredictors of treatmentCancer patientsRadical prostatectomyProstate cancerMuscle-invasive urothelial bladder cancerNegative predictors of treatmentBlack raceNational Cancer DatabaseNonmetastatic prostate cancerUrothelial bladder cancerProstate cancer patientsBladder cancer patientsMultivariate logistic regression modelAssociated with lower ratesKidney cancer patientsPrivate insurance statusAssociated with lower oddsAssociated with greater oddsLow-volume hospitalsRadical cystectomyReceipt of treatmentGenitourinary malignanciesPerioperative morbidity
2019
Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorBone Morphogenetic Protein 4Cell-Free Nucleic AcidsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGTPase-Activating ProteinsHumansMaleMiddle AgedNuclear ProteinsPrognosisSurvival AnalysisUrinary Bladder NeoplasmsConceptsProgression-free survivalCox regression analysisRecurrence-free survivalDisease recurrenceBladder cancerNon-muscle invasive bladder cancerInvasive bladder cancer patientsWorse progression-free survivalMultivariate Cox regression analysisWorse recurrence-free survivalKaplan-Meier analysisKaplan-Meier curvesBladder cancer patientsRegression analysisUrinary cell-free DNAValuable novel biomarkersCell-free DNANMIBC patientsClinical outcomesCancer patientsDisease progressionPrognostic markerReal-time PCRNovel biomarkersIndependent factorsPD13-10 ONCOLOGICAL OUTCOMES OF BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH POSTOPERATIVE CHEMOHYPERTHERMIA: A MULTICENTRE EUROPEAN RETROSPECTIVE ANALYSIS.
Tan* W, Hendricksen K, Wilby D, Nzeh C, Goizueta J, Vilmar W, Bello A, Sousa A, Morena J, Pontones J, Guerrero F, Kalchev I, Frank E, Boormans J. PD13-10 ONCOLOGICAL OUTCOMES OF BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH POSTOPERATIVE CHEMOHYPERTHERMIA: A MULTICENTRE EUROPEAN RETROSPECTIVE ANALYSIS. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555390.06113.0b.Peer-Reviewed Original ResearchMP32-10 COMPARATIVE EFFECTIVENESS OF ROBOTIC ASSISTED AND OPEN RADICAL CYSTECTOMY IN CONTEMPORARY COHORTS OF BLADDER CANCER PATIENTS: AN INTERNATIONAL MULTICENTER COLLABORATION
Zamboni* S, Soria F, Mathieu R, Xylinas E, D'Andrea D, Abufaraj M, Tan W, Kelly J, Simone G, Gallucci M, Meraney A, Krishna S, Konety B, Montorsi F, Briganti A, Mattei A, Baumeister P, Antonelli A, Simeone C, Rink M, Aziz A, Karakiewicz P, Rouprêt M, Perry M, Rowe E, Koupparis A, Scherr D, Ploussard G, Sooriakumaran P, Shariat S, Moschini M. MP32-10 COMPARATIVE EFFECTIVENESS OF ROBOTIC ASSISTED AND OPEN RADICAL CYSTECTOMY IN CONTEMPORARY COHORTS OF BLADDER CANCER PATIENTS: AN INTERNATIONAL MULTICENTER COLLABORATION. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555883.61031.df.Peer-Reviewed Original Research843 Comparative effectiveness of robotic assisted and open radical cystectomy in contemporary cohorts of bladder cancer patients: An international multicenter collaboration
Zamboni S, Soria F, Mathieu R, Xylinas E, Tan W, Kelly J, Simone G, Gallucci M, Meraney A, Konety B, Antonelli A, Simeone C, Baumeister P, Mattei A, Montorsi F, Briganti A, Rink M, Aziz A, Karakiewicz P, Rouprêt M, Scherr D, Ploussard G, Sooriakumaran P, Shariat S, Moschini M, Urologists U. 843 Comparative effectiveness of robotic assisted and open radical cystectomy in contemporary cohorts of bladder cancer patients: An international multicenter collaboration. European Urology Open Science 2019, 18: e1139-e1140. DOI: 10.1016/s1569-9056(19)30821-8.Peer-Reviewed Original Research
2018
Novel urinary biomarkers for the detection of bladder cancer: A systematic review
Tan W, Tan W, Tan M, Khetrapal P, Dong L, deWinter P, Feber A, Kelly J. Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 69: 39-52. PMID: 29902678, DOI: 10.1016/j.ctrv.2018.05.012.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueUrinary biomarkersBladder cancerReceiver Operating CharacteristicRisk of biasPredictive valueNon-muscle invasive bladder cancer patientsBiomarkers investigated to dateInvasive bladder cancer patientsDetection of bladder cancerDiagnosis of bladder cancerSystematic reviewNovel urinary biomarkersBladder cancer patientsQUADAS-2 toolCase-control studyAssessed risk of biasSpecificity of biomarkersPositive test resultsSystematic searchUrinary cytologySurveillance cystoscopyComprehensive systematic reviewQUADAS-2
2016
The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer
Casey M, Wisnivesky J, Le V, Sarpel U, Stensland K, Oh W, Galsky M. The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer 2016, 2: 319-327. PMID: 27500199, PMCID: PMC4969695, DOI: 10.3233/blc-160058.Peer-Reviewed Original ResearchNew York State populationNew York StateDepartment of HealthMedian travel distanceClassifying hospitalsGeographic accessGeographic disparitiesSimultaneously improving accessInpatient admissionsUS CensusAssociated with improved outcomesPopulation weightsPatient distanceHigh-volume centersCystectomy volumeHospitalCancer patientsStudy periodBladder cancerVolume centersMedian distanceGeographical barriersTravel distancePopulationBladder cancer patientsComparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement
Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Mohamed N, Tsao C, Boffetta P, Wiklund P, Oh W, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal Of Clinical Oncology 2016, 34: 2627-2635. PMID: 27269939, PMCID: PMC5012691, DOI: 10.1200/jco.2016.67.5033.Peer-Reviewed Original ResearchConceptsCombined-modality therapyLymph node involvementTreated with chemotherapyOverall survivalAdjuvant chemotherapyBladder cancerPreoperative chemotherapyNode involvementDistant metastasisChemotherapy trialsClinical evidence of regional lymph node involvementSurvival of patients treated with chemotherapyTreatment strategiesClinical lymph node involvementEvidence of regional lymph node involvementRegional lymph node involvementNational Cancer Data BasePatients treated with chemotherapyFirst-line chemotherapy trialsNeoadjuvant chemotherapy trialsTreated with cystectomyEffectiveness of treatment strategiesBladder cancer patientsLong-term survivalCystectomyAssociation of nineteen polymorphisms from seven DNA repair genes and the risk for bladder cancer in Gansu province of China
Zhu G, Su H, Lu L, Guo H, Chen Z, Sun Z, Song R, Wang X, Li H, Wang Z. Association of nineteen polymorphisms from seven DNA repair genes and the risk for bladder cancer in Gansu province of China. Oncotarget 2016, 7: 31372-31383. PMID: 27153553, PMCID: PMC5058763, DOI: 10.18632/oncotarget.9146.Peer-Reviewed Original ResearchConceptsBladder cancerChinese populationDNA repair genesBladder cancer patientsMaximal testing accuracyRepair genesHan Chinese populationCross-validation consistencyNorthwest Chinese populationCancer patientsHealthy controlsElevated riskSignificant associationHaplotype GTCancerDNA repair-associated genesRepair-associated genesXRCC3 geneRisk
2015
2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo
Petrylak D, Eigl B, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar S, Sternberg C, Retz M, Blumenstein B, Jacobs C, Stewart P, Bellmunt J. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. European Journal Of Cancer 2015, 51: s525. DOI: 10.1016/s0959-8049(16)31454-x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply